Dr. Pavlos Msaouel, MD, PhD

Dr. Msaouel practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Msaouel's NPI, 1154617983, was assigned on June 20, 2011. Dr. Msaouel graduated from University of Athens in 2006. Dr. Msaouel holds Texas license R0762.

Dr. Msaouel's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Msaouel's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Texas Children's Hospital. Dmand AI also links Dr. Msaouel to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Msaouel practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Msaouel's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Msaouel is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Msaouel's licenses on file in 11 states: Texas, Florida, Arizona, Tennessee, Washington, Georgia, Louisiana, Alabama, Mississippi, Oklahoma and New York.

Dmand AI lists circulatory problems in extremities, fibromyalgia and chronic pain, gastrointestinal infection, gastrointestinal inflammation and urinary tract infection among the conditions Dr. Msaouel treats.

CMS data shows 136 Medicare services from Dr. Msaouel across 4 procedure codes in 2024, for 70 Medicare patients. Medicare paid $13,602 for them.

CMS counts 70 Medicare patients who saw Dr. Msaouel in 2024. The largest group is 65 to 74, with 40 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 3.42, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Msaouel's median patient age at 68, with 31% women.

In 2024, Dr. Msaouel wrote 130 Medicare Part D claims for 45 patients. 80% of them were for generic drugs. CMS names the drug for 33 of them, across 2 drugs with 11 or more claims each, at $6,021 in total drug cost. In 2023, CMS named 30 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Msaouel for performance year 2024, reported as part of a group. Dr. Msaouel accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Msaouel as offering telehealth.

Dmand AI links 227 papers to Dr. Msaouel, published from 2006 to 2025. 2021 was the busiest year, with 26. The most frequent topics are Kidney Neoplasms, Carcinoma, Renal Cell and Antineoplastic Agents. Dr. Msaouel has published most often in Anticancer Res. Dr. Msaouel's most frequent co-authors are Nizar M. Tannir, MD, Amishi Y. Shah, MD and Eric Jonasch, MD.

Dmand AI links Dr. Msaouel to 5 clinical trials, 3 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Carcinoma, Renal Cell, Kidney Neoplasms and Clear-cell metastatic renal cell carcinoma. M.D. Anderson Cancer Center sponsors the most, 4.

CMS Open Payments shows 96 general payments to Dr. Msaouel from 14 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 36% of the total. Pfizer Inc. paid the most, $19,996.

Dr. Msaouel graduated from University of Athens in 2006. Dr. Msaouel is a member of ASCO.

Dr. Msaouel is in network with 4 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Cigna. PPO plans come from the most carriers, 3. Check the plan with the practice before a visit.